Roeder A, Schaller M, Schäfer-Korting M, Korting H C
Klinik und Poliklinik für Dermatologie und Allergologie, Ludwig-Maximilians-Universität, Frauenlobstrasse 9-11, DE-80337 Munich, Germany.
Skin Pharmacol Physiol. 2004 May-Jun;17(3):111-8. doi: 10.1159/000077236.
Tazarotene is a member of the new generation of receptor-selective, synthetic retinoids for the topical treatment of mild to moderate plaque psoriasis, acne vulgaris and photoaging. Though they are effective in monotherapy, clinical studies with a focus on novel combination treatments and a comparison of different agents for these skin disorders are accumulating. The concomitant use of tazarotene with a mid-potency or high-potency corticosteroid enhances the efficacy in psoriatic plaques and reduces the risk of steroid-induced skin atrophy. Combining phototherapy with adjunctive tazarotene accelerates the clinical response and reduces the cumulative UVB or PUVA exposure load. Tazarotene applied once daily is superior to adapalene monotherapy in acne vulgaris and is efficacious in the treatment of photodamage. Novel therapeutic regimens such as short-contact therapy have been developed for both acne and psoriasis in order to diminish the major adverse events like pruritus, burning, local skin irritation and erythema.
他扎罗汀是新一代受体选择性合成维甲酸类药物的一种，用于局部治疗轻至中度斑块状银屑病、寻常痤疮和光老化。尽管它们单药治疗有效，但聚焦于新型联合治疗以及针对这些皮肤疾病比较不同药物的临床研究正在不断积累。他扎罗汀与中效或高效皮质类固醇联合使用可提高银屑病斑块的疗效，并降低类固醇诱导的皮肤萎缩风险。光疗与辅助性他扎罗汀联合使用可加速临床反应，并减少累积的紫外线B或补骨脂素紫外线A暴露量。每日一次外用他扎罗汀在寻常痤疮治疗中优于阿达帕林单药治疗，且对光损伤治疗有效。为痤疮和银屑病开发了诸如短接触疗法等新型治疗方案，以减少瘙痒、灼烧、局部皮肤刺激和红斑等主要不良事件。
